Wright Medical Group, Inc. (NASDAQ: WMGI), a global orthopaedic medical device company, is pleased to sponsor a live webcast covering diabetic foot ulcer treatment utilizing the Company's GRAFTJACKET® Ulcer Repair Matrix. The live webcast will take place Thursday, October 13, 2005 at 7:00 p.m. Central Time The event will also be archived on this site for twelve months.

The webcast will include a surgical demonstration focusing on the scientific aspects of GRAFTJACKET® Ulcer Repair Matrix's advanced grafting technology and how this material offers a unique alternative for treating challenging diabetic foot ulcers. An interactive question and answer session will also be featured for participants of the live web event. The webcast will be moderated by David G. Armstrong, DPM, Ph.D., Assistant Dean and Professor of Surgery at the Dr. William M. Scholl College of Podiatric Medicine in North Chicago, IL and will be hosted on campus.

Joining Dr. Armstrong will be Stephen A. Brigido, DPM of East Stroudsburg, PA's Foot and Ankle Center at Coordinated Health, who will perform the surgical demonstration, and Harry Goldsmith, DPM of CodingLine, who will lead a discussion on Medicare reimbursement for diabetic foot wound treatment with GRAFTJACKET® Ulcer Repair Matrix, which is fully reimbursable by Medicare in all standard treatment settings. Through these added discussions, Wright hopes to give surgeon participants a complete view of GRAFTJACKET® Ulcer Repair Matrix as the advanced choice for their challenging wound repair needs.

In the United States alone, diabetes-related foot ulcers account for approximately 70,000 lower extremity amputations each year. Most traditional foot ulcer products have required multiple treatments to achieve complete wound repair. Wright's GRAFTJACKET® Ulcer Repair Matrix offers a treatment option that allows the body to regenerate new tissue at deep levels of the wound, while protecting the wound surface with a scaffold that actually converts into functional host tissue. In most cases, this treatment, along with wound dressing and off loading, results in full wound repair after only one procedure. Data accepted for publication demonstrates that treatment with GRAFTJACKET® Ulcer Repair Matrix is 85% (17/20) effective at 12 weeks, compared to 5% (1/20) effectiveness for conventional treatment in Wagner Grade I and II wounds. Compared to conventional treatment alone, Wright's GRAFTJACKET® Ulcer Repair Matrix offers physicians and their patients an option for potentially faster and less costly wound repair.

"The upcoming webcast will serve as a one-stop resource for surgeons to learn detailed information about all aspects of GRAFTJACKET® Ulcer Repair Matrix – from ease of use to options for reimbursement," said John T. Treace, Vice President and General Manager of Wright's Bio-Extremity Division. "We are extremely pleased to offer interested surgeons such a complete overview of Wright's cutting-edge option for diabetic foot ulcer repair."

About Wright
Wright Medical Group, Inc. is a global orthopaedic medical device company specializing in the design, manufacture and marketing of reconstructive joint devices and biologics. The Company has been in business for more than 50 years and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit our website at www.wmt.com.

View Webcast